Emerging Markets Earnings Roundup: GSK And Novo Nordisk (Part 5)
This article was originally published in PharmAsia News
Executive Summary
GSK CEO Andrew Witty was unmistakably bullish on emerging markets and in particular China, while Novo Nordisk’s Lars Sorensen has felt the pinch from pricing pressure in China, and cautioned about further cuts to its bread and butter insulin business.